FDA-approval for Roche’s nucleic acid based (PCR) Rapid Mycoplasma Test (MycoTOOL® PCR Mycoplasma Detection Kit)
Recommendation

3-6 November 2026
Vienna, Austria
Requirements, Measures and Strategies
On November 1st, 2012, the MycoTOOL® PCR Mycoplasma Detection Kit-based test from Roche Applied Science was approved by the U.S. Food and Drug Administration (FDA) for release testing of a Roche biopharmaceutical product. It is the first commercially available Mycoplasma PCR test approved by FDA that can replace conventional and time-consuming mycoplasma detection assays (culture method as well as indicator cell culture method) for the testing of biologics and biopharmaceuticals.
In the past three years Roche’s nucleic acid based (PCR) rapid mycoplasma test has been approved by the European Medicines Agency (EMA), the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) and more than 100 additional Health Authorities worldwide as a Mycoplasma PCR test for release testing of several biopharmaceutical products. The MycoTOOL® PCR Mycoplasma Detection Kit providing all critical reagents for performing an easy to use sample preparation and PCR is globally available for use.
On this occasion, an additional lecture about the MycoTool and the way to get the approval was added to the agenda of the Rapid Microbiological Methods Conference on 11 and 12 December 2013 in Munich.
Related GMP News
08.04.2026Significant Deficiencies in Microbiological and Analytical Quality Control
01.04.2026FDA Warning Letter: Significant Violations of Aseptic Manufacturing Procedures uncovered
28.01.2026Warning Letter: Microbiological OOS and Inadequate Microbiological Method Validation
12.11.2025Bioburden in the Focus of Pharmaceutical Quality
22.10.2025MAT Survey by the British NC3Rs
03.09.2025FDA Warning Letter to Swedish Company - from Microbiology to Maintenance

